An oncogenic role for DNMT3B is observed in several hematological cancers, including T-ALL, AML, and Burkitt and diffuse large B-cell lymphoma (DLBCL), where increased DNMT3B levels are reported to be mostly the result of increased MYC-levels. This evidence concerns the gene DNMT3B and acute myeloid leukemia.